Hemophilia A, a lifelong bleeding disorder, often causes spontaneous or injury-related bleeding, most commonly in large ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...

The Indian Council of Medical Research's National Institute of Immunohaematology (ICMR's NIIH) has developed a cost-effective ...

Scientists from Cincinnati Children's and colleagues based in Japan report achieving a major step forward in organoid ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...

A simple and affordable point-of-care test kit has been indigenously developed by the National Institute of Immunohaematology for early diagnosis of genetic bleeding disorders haemophilia A and Von ...

The National Institute of Immunohaematology has developed a cost-effective test kit for early diagnosis of hemophilia A and ...

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

A patient at Guy’s and St Thomas’ recently received the first treatment in the UK of a new, potentially life-changing ...

The first patient in the UK has been treated by the NHS with CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene ...